Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

(2016) M. Nauck   DIABETES OBESITY & METABOLISM

Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database

(2016) Jil Mamza et al.   Diabetes Technology & Therapeutics

Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism

(2016) Bo Ahrén et al.   DIABETOLOGIA

Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials

(2016) S. Del Prato et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations

(2016) Antonio Ceriello et al.   Journal of Diabetes Investigation

Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies

(2015) Matteo Monami et al.   ACTA DIABETOLOGICA

Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review

(2015) Shashank R Joshi et al.   EXPERT OPINION ON PHARMACOTHERAPY

Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients

(2015) Daisuke Yabe et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

(2015) Jennifer B. Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial

(2015) Yuhong Chen et al.   Journal of Diabetes Investigation

Correlation of the incretin effect with first- and second-phase insulin secretions in Koreans with various glucose tolerance statuses

(2014) Tae Jung Oh et al.   CLINICAL ENDOCRINOLOGY

Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database

(2014) Jianping Weng et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease

(2013) Jennifer B. Green et al.   AMERICAN HEART JOURNAL

Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States

(2013) Ronald C.W. Ma et al.   Annals of the New York Academy of Sciences

Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus

(2013) Christian Friedrich et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

(2013) Y. G. Kim et al.   DIABETOLOGIA

Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin

(2012) Yan-Ling He   CLINICAL PHARMACOKINETICS

Acculturation, nutrition, and health disparities in Latinos

(2011) Rafael Pérez-Escamilla   AMERICAN JOURNAL OF CLINICAL NUTRITION

Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study

(2011) Soo Lim et al.   CLINICAL ENDOCRINOLOGY

Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1

(2011) D. R. Owens et al.   DIABETIC MEDICINE

Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea

(2011) Yoshimasa Aso et al.   Translational Research

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2010) M.-R. Taskinen et al.   DIABETES OBESITY & METABOLISM

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

(2010) S. Del Prato et al.   DIABETES OBESITY & METABOLISM

Synergistic effect of α-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment

(2010) Yukio Horikawa et al.   Journal of Diabetes Investigation

Diabetes in Asia

(2009) Ambady Ramachandran et al.   LANCET